Zyversa Therapeutics Inc (ZVSA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 12-2024 | 09-2024 | 06-2024 | 03-2024 | 12-2023 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 1,531 | 123 | 120 | 2,034 | 3,138 |
| TOTAL | $1,716 | $390 | $641 | $2,900 | $3,353 |
| Non-Current Assets | |||||
| PPE Net | N/A | 0 | 2 | 4 | 7 |
| Intangibles | 18,648 | 18,648 | 18,648 | 18,648 | 18,648 |
| Other Non-Current Assets | 236 | 386 | 179 | 99 | 106 |
| TOTAL | $18,884 | $19,034 | $18,828 | $18,751 | $18,761 |
| Total Assets | $20,599 | $19,424 | $19,470 | $21,651 | $22,114 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 9,337 | 9,285 | 8,317 | 8,128 | 8,432 |
| Accrued Expenses | 1,894 | 2,257 | 1,678 | 1,455 | 1,755 |
| TOTAL | $11,231 | $11,542 | $9,995 | $9,583 | $10,195 |
| Non-Current Liabilities | |||||
| TOTAL | $852 | $855 | $855 | $845 | $845 |
| Total Liabilities | $12,083 | $12,397 | $10,850 | $10,428 | $11,040 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 2,568 | 2,344 | 1,029 | 835 | 759 |
| Retained earnings | -112,633 | -111,211 | -108,810 | -106,046 | -103,219 |
| Other shareholders' equity | -7 | -7 | -7 | -7 | -7 |
| TOTAL | $8,516 | $7,027 | $8,620 | $11,223 | $11,075 |
| Total Liabilities And Equity | $20,599 | $19,424 | $19,470 | $21,651 | $22,114 |